Reta
Retatrutide (Research Peptide)
For Research Use Only – Not for Human Consumption, Diagnostic, or Therapeutic Use. Retatrutide is supplied strictly for laboratory and scientific research applications, such as in vitro and in vivo studies on multi-receptor agonism, metabolic regulation, energy expenditure, appetite signaling, body composition, and obesity or diabetes models. All information below is for educational and research reference only and does not constitute medical advice.
What Is Retatrutide?
Retatrutide (also known as LY3437943) is a synthetic 39-amino acid peptide designed as a triple receptor agonist targeting the glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). It is based on a GIP backbone with strategic modifications, including non-natural amino acids (such as Aib at positions 2 and 20, α-methyl-leucine) and a C20 fatty diacid moiety attached via a linker at a lysine residue. These modifications enhance receptor potency balance, enzymatic stability, and extend its half-life to approximately 6 days, supporting once-weekly dosing in research protocols.
lyophilized powder (acetate or similar salt form) for reconstitution in research settings.
Mechanism of Action (Research Context)
In laboratory models, retatrutide functions as a unimolecular triple agonist with a tailored potency profile: enhanced activity at the GIPR (approximately 8.9-fold relative to native GIP), while showing reduced potency at GLP-1R (0.4-fold) and GCGR (0.3-fold) compared to their endogenous ligands. This balanced activation leads to:
GLP-1R agonism: Suppresses appetite, slows gastric emptying, and enhances glucose-dependent insulin secretion.
GIPR agonism: Further supports insulin secretion, improves lipid metabolism, and may reduce certain gastrointestinal side effects observed with GLP-1-only agonists.
GCGR agonism: Increases energy expenditure (thermogenesis), promotes lipolysis and hepatic fat oxidation, and contributes to fat mass reduction.
The combined effects result in reduced caloric intake, elevated energy expenditure, and favorable shifts in nutrient partitioning—particularly targeting visceral and hepatic fat in research models. Unlike single or dual agonists, the addition of glucagon receptor activity is studied for its potential to drive greater overall weight loss and metabolic improvements while preserving lean mass in certain contexts.
Key Research Findings and Potential Areas of Study
Retatrutide has been investigated in controlled research settings, notably in models of obesity, type 2 diabetes, and metabolic dysfunction-associated steatotic liver disease (MASLD/MASH). Highlights from published phase 2 studies include:
Substantial Body Weight Reduction: Dose-dependent weight loss, with the 12 mg group showing mean reductions of approximately 17.5% at 24 weeks and 24.2% at 48 weeks (vs. ~2% with placebo). Weight loss trajectories often continued without clear plateau at study endpoints, and a high percentage of subjects (up to 100% at higher doses) achieved ≥5% loss, with notable portions reaching ≥20–30% in top-dose arms.
Improvements in Body Composition: Significant reductions in waist circumference (up to ~19–20 cm) and preferential loss of visceral and abdominal fat, alongside improvements in fat quality and potential relative preservation of lean mass compared to some caloric-deficit models.
Metabolic and Cardiometabolic Markers: Reductions in HbA1c, fasting glucose, insulin levels, blood pressure, and triglycerides; favorable shifts in lipid profiles; and high rates of achieving normoglycemia in prediabetic subjects. Liver fat content showed marked relative reductions (up to 80+% at higher doses), with many participants normalizing liver fat (<5%).
Additional Endpoints: Enhanced energy expenditure, delayed gastric emptying, and potential benefits in models of hepatic steatosis and insulin sensitivity.
Ongoing research explores its utility in broader metabolic regulation, energy balance, and multi-receptor crosstalk in adiposity, diabetes, and related conditions.
Why Researchers Choose Retatrutide
Retatrutide is valued as a next-generation tool for studying triple agonism due to its unprecedented weight loss magnitude in models, combined effects on intake reduction and expenditure increase, and potential advantages in visceral/hepatic fat targeting over dual or single agonists. It serves as an excellent probe for:
Multi-hormonal regulation of metabolism
Appetite and satiety pathways
Energy homeostasis and thermogenesis
Body recomposition and cardiometabolic health in obesity/diabetes models
Storage for Research: Lyophilized powder is stable at –20°C. Reconstituted solutions should be handled according to standard peptide protocols (typically with bacteriostatic water) and used promptly.
If you are investigating incretin/glucagon pathways, advanced obesity models, or synergistic receptor targeting, retatrutide provides a potent, well-documented research compound with extensive published data.
Questions about specifications, COA, purity, or research applications? Contact our support team—we’re here to support legitimate scientific inquiry.
All products are for research purposes only. Not intended for human use.
